NASDAQ:LMAT - LeMaitre Vascular Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding LeMaitre Vascular Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.29 -0.23 (-0.98 %) (As of 04/2/2020 01:43 PM ET) Add Compare Today's Range$22.78Now: $23.29▼$24.2250-Day Range$21.03MA: $26.94▼$30.7452-Week Range$18.76Now: $23.29▼$38.64Volume3,189 shsAverage Volume183,743 shsMarket Capitalization$469.99 millionP/E Ratio26.47Dividend Yield1.52%Beta1.43 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LMAT Previous Symbol CUSIPN/A CIK1158895 Webhttp://www.lemaitre.com/ Phone781-221-2266Debt Debt-to-Equity Ratio0.09 Current Ratio4.42 Quick Ratio2.52Price-To-Earnings Trailing P/E Ratio26.47 Forward P/E Ratio25.04 P/E Growth3.2 Sales & Book Value Annual Sales$117.23 million Price / Sales4.01 Cash Flow$1.09 per share Price / Cash Flow21.34 Book Value$7.41 per share Price / Book3.14Profitability EPS (Most Recent Fiscal Year)$0.88 Net Income$17.93 million Net Margins15.30% Return on Equity12.85% Return on Assets10.58%Miscellaneous EmployeesN/A Outstanding Shares20,180,000Market Cap$469.99 million Next Earnings Date5/6/2020 (Estimated) OptionableOptionable Receive LMAT News and Ratings via Email Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:LMAT Rates by TradingView LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions How has LeMaitre Vascular's stock been impacted by COVID-19 (Coronavirus)? LeMaitre Vascular's stock was trading at $26.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LMAT stock has decreased by 10.8% and is now trading at $23.29. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of LeMaitre Vascular? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for LeMaitre Vascular. When is LeMaitre Vascular's next earnings date? LeMaitre Vascular is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for LeMaitre Vascular. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular Inc (NASDAQ:LMAT) posted its quarterly earnings data on Thursday, February, 6th. The medical instruments supplier reported $0.23 EPS for the quarter, hitting the Zacks' consensus estimate of $0.23. The medical instruments supplier earned $30.20 million during the quarter, compared to analysts' expectations of $30.44 million. LeMaitre Vascular had a net margin of 15.30% and a return on equity of 12.85%. LeMaitre Vascular's revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.30 earnings per share. View LeMaitre Vascular's earnings history. How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular? LeMaitre Vascular announced a quarterly dividend on Monday, February 10th. Stockholders of record on Tuesday, March 3rd will be paid a dividend of $0.095 per share on Thursday, March 19th. This represents a $0.38 dividend on an annualized basis and a dividend yield of 1.63%. The ex-dividend date is Monday, March 2nd. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.09. View LeMaitre Vascular's dividend history. What guidance has LeMaitre Vascular issued on next quarter's earnings? LeMaitre Vascular issued an update on its FY20 earnings guidance on Thursday, February, 6th. The company provided EPS guidance of $0.90-$0.98 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.95. The company issued revenue guidance of $127.4-$130.8 million, compared to the consensus revenue estimate of $129.41 million. What price target have analysts set for LMAT? 5 brokerages have issued 12-month target prices for LeMaitre Vascular's shares. Their forecasts range from $38.00 to $40.00. On average, they expect LeMaitre Vascular's share price to reach $39.00 in the next year. This suggests a possible upside of 67.5% from the stock's current price. View analysts' price targets for LeMaitre Vascular. What are Wall Street analysts saying about LeMaitre Vascular stock? Here are some recent quotes from research analysts about LeMaitre Vascular stock: 1. According to Zacks Investment Research, "LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. " (2/12/2020) 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on LMAT shares and are increasing our price target to $32 (from $30 previously) given the encouraging organic growth (and particularly the strong unit volume growth). We think margins will expand meaningfully (vs. Q1) for the remainder of FY/19 and step up again in FY/20 as recently-hired sale reps become increasingly productive. We arrive at our target by attaching a 20x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $60 million in net cash 12 months from now." (5/2/2019) Has LeMaitre Vascular been receiving favorable news coverage? Headlines about LMAT stock have been trending very negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. LeMaitre Vascular earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutLeMaitre Vascular. Are investors shorting LeMaitre Vascular? LeMaitre Vascular saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 1,696,500 shares, a decrease of 15.2% from the February 27th total of 2,000,000 shares. Based on an average daily volume of 143,400 shares, the days-to-cover ratio is currently 11.8 days. Currently, 10.2% of the company's shares are sold short. View LeMaitre Vascular's Current Options Chain. Who are some of LeMaitre Vascular's key competitors? Some companies that are related to LeMaitre Vascular include Merit Medical Systems (MMSI), Cantel Medical (CMD), Glaukos (GKOS), AtriCure (ATRC), Inspire Medical Systems (INSP), Luminex (LMNX), Cardiovascular Systems (CSII), Atrion (ATRI), Inovio Pharmaceuticals (INO), Shockwave Medical (SWAV), Silk Road Medical (SILK), Axonics Modulation Technologies (AXNX), Cerus (CERS), Tactile Systems Technology (TCMD) and OraSure Technologies (OSUR). What other stocks do shareholders of LeMaitre Vascular own? Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include Canopy Growth (CGC), AbbVie (ABBV), Sociedad Quimica y Minera de Chile (SQM), Gilead Sciences (GILD), NVIDIA (NVDA), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), Adobe (ADBE), Boeing (BA) and AT&T (T). Who are LeMaitre Vascular's key executives? LeMaitre Vascular's management team includes the following people: Mr. George W. LeMaitre, Chairman & CEO (Age 54)Mr. David B. Roberts, Pres & Director (Age 55)Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 54)Mr. Trent G. Kamke, Sr. VP of Operations (Age 48)Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 85) What is LeMaitre Vascular's stock symbol? LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT." How do I buy shares of LeMaitre Vascular? Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is LeMaitre Vascular's stock price today? One share of LMAT stock can currently be purchased for approximately $23.29. How big of a company is LeMaitre Vascular? LeMaitre Vascular has a market capitalization of $469.99 million and generates $117.23 million in revenue each year. The medical instruments supplier earns $17.93 million in net income (profit) each year or $0.88 on an earnings per share basis. View additional information about LeMaitre Vascular. What is LeMaitre Vascular's official website? The official website for LeMaitre Vascular is http://www.lemaitre.com/. How can I contact LeMaitre Vascular? LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266. MarketBeat Community Rating for LeMaitre Vascular (NASDAQ LMAT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 452 (Vote Outperform)Underperform Votes: 316 (Vote Underperform)Total Votes: 768MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/2/2020 by MarketBeat.com StaffFeatured Article: What are the disadvantages of after-hours trading?
